Evaluate Recovery of Testosterone for Patients Using Eligard

Inclusion Criteria

• Must be outpatient, not hospitalized
• Male Patient between ages 50-80, inclusive
• Histologically/Cytologically graded adenocarcinoma of the prostate
• Must have T1, T2 or T3a adenocarcinoma of the prostate
• Must be a candidate for radiation therapy. Hormone refractory patients excluded
• WHO/ECOG score of 0,1 or 2

Exclusion Criteria

• NO evidence of urinary tract that would put the patient at risk in the opinion of the Investigator.
• Used the following treatments for prostate Cancer

*immunotherapy *chemotherapy *External Beam Radiation *brachytherapy *hormonal therapy *biological response modifiers

• Prior Prostate Surgery (excluding TUNA or TURP)
• Undergone Orchiectomy, adrenalectomy, hypophysectomy or be receiving any product which could alter the function of these organs
• Use of Investigational Drug, Biologic or device within five half-lives of its physiological action or three months prior to base line, whichever is longer
• Over the counter or alternative medical therapies which have estrogenic or anti-androgenic effect
• uncontrolled CHF within 6 months to baseline
• Myocardial Infarct, coronary vascular procedure or Clinically SignificantCardiovascualr Disease within 6 months of baseline Visit
• Venous thrombosis with in 6 Months of Screening
• Uncontrolled Hypertension defined as >170/100 or Symptomatic Hypotension within 3 months of Baseline
• Insulin dependant Diabetic Patients Must not administer in an anatomic region where they will receive Eligard.
• Drug or Alcohol Abuse 6 months prior to Baseline
• Other Serious Illness at the discretion of the Investigator
• Patients receiving anti-coagulant or anti-platlet medication must be on a stable dose for 3 months prior to Baseline
• Hypersensitivity to GnRH, GnRH agonists